These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 19636278

  • 1. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
    Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connor EM, Losonsky GA.
    Pediatr Infect Dis J; 2009 Sep; 28(9):835-7. PubMed ID: 19636278
    [Abstract] [Full Text] [Related]

  • 2. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children.
    Abarca K, Jung E, Fernández P, Zhao L, Harris B, Connor EM, Losonsky GA, Motavizumab Study Group.
    Pediatr Infect Dis J; 2009 Apr; 28(4):267-72. PubMed ID: 19258920
    [Abstract] [Full Text] [Related]

  • 3. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
    Weisman LE.
    Curr Opin Mol Ther; 2009 Apr; 11(2):208-18. PubMed ID: 19330726
    [Abstract] [Full Text] [Related]

  • 4. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.
    J Mol Biol; 2007 May 04; 368(3):652-65. PubMed ID: 17362988
    [Abstract] [Full Text] [Related]

  • 5. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
    Ramilo O, Lagos R, Sáez-Llorens X, Suzich J, Wang CK, Jensen KM, Harris BS, Losonsky GA, Griffin MP, Motavizumab Study Group.
    Pediatr Infect Dis J; 2014 Jul 04; 33(7):703-9. PubMed ID: 24356256
    [Abstract] [Full Text] [Related]

  • 6. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 04; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 7. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season.
    Fernández P, Trenholme A, Abarca K, Griffin MP, Hultquist M, Harris B, Losonsky GA, Motavizumab Study Group.
    BMC Pediatr; 2010 Jun 03; 10():38. PubMed ID: 20525274
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, Moulton LH, Losonsky GA, Karron RA, Santosham M, Respiratory Syncytial Virus (RSV) Prevention study group.
    Lancet Infect Dis; 2015 Dec 03; 15(12):1398-408. PubMed ID: 26511956
    [Abstract] [Full Text] [Related]

  • 9. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
    Carbonell-Estrany X.
    Pediatr Infect Dis J; 2003 Feb 03; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
    [Abstract] [Full Text] [Related]

  • 10. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.
    Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA, Motavizumab Study Group.
    Pediatrics; 2010 Jan 03; 125(1):e35-51. PubMed ID: 20008423
    [Abstract] [Full Text] [Related]

  • 11. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants.
    DeVincenzo JP, Hall CB, Kimberlin DW, Sánchez PJ, Rodriguez WJ, Jantausch BA, Corey L, Kahn JS, Englund JA, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM.
    J Infect Dis; 2004 Sep 01; 190(5):975-8. PubMed ID: 15295704
    [Abstract] [Full Text] [Related]

  • 12. Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.
    Schepens B, Ibañez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P, Vervalle F, Verrips T, Melero J, Vandevelde W, Vanlandschoot P, Saelens X.
    J Infect Dis; 2011 Dec 01; 204(11):1692-701. PubMed ID: 21998474
    [Abstract] [Full Text] [Related]

  • 13. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
    Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O.
    Pediatr Infect Dis J; 2007 Dec 01; 26(12):1089-93. PubMed ID: 18043443
    [Abstract] [Full Text] [Related]

  • 14. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR, Hoopes JM, Hemming VG.
    Adv Ther; 2011 Feb 01; 28(2):110-25. PubMed ID: 21318605
    [Abstract] [Full Text] [Related]

  • 15. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR.
    Expert Rev Anti Infect Ther; 2011 Jan 01; 9(1):27-32. PubMed ID: 21171875
    [Abstract] [Full Text] [Related]

  • 16. Respiratory syncytial virus infections: recent prospects for control.
    Sidwell RW, Barnard DL.
    Antiviral Res; 2006 Sep 01; 71(2-3):379-90. PubMed ID: 16806515
    [Abstract] [Full Text] [Related]

  • 17. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK.
    Pediatr Infect Dis J; 2004 Jan 01; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [Abstract] [Full Text] [Related]

  • 18. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
    Huang K, Incognito L, Cheng X, Ulbrandt ND, Wu H.
    J Virol; 2010 Aug 01; 84(16):8132-40. PubMed ID: 20519399
    [Abstract] [Full Text] [Related]

  • 19. Prevention of respiratory syncytial virus infection among Puerto Rican infants.
    Winchester L, García L, García I, Concepción CB.
    P R Health Sci J; 2002 Sep 01; 21(3):191-3. PubMed ID: 12243108
    [Abstract] [Full Text] [Related]

  • 20. Respiratory syncytial virus infections: characteristics and treatment.
    Chidgey SM, Broadley KJ.
    J Pharm Pharmacol; 2005 Nov 01; 57(11):1371-81. PubMed ID: 16259768
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.